AU2016247319A1 - Methods for treating cancer - Google Patents

Methods for treating cancer Download PDF

Info

Publication number
AU2016247319A1
AU2016247319A1 AU2016247319A AU2016247319A AU2016247319A1 AU 2016247319 A1 AU2016247319 A1 AU 2016247319A1 AU 2016247319 A AU2016247319 A AU 2016247319A AU 2016247319 A AU2016247319 A AU 2016247319A AU 2016247319 A1 AU2016247319 A1 AU 2016247319A1
Authority
AU
Australia
Prior art keywords
cancer
compound
paclitaxel
formula
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016247319A
Other languages
English (en)
Inventor
Yuan Gao
Matthew J. Hitron
Chiang J. Li
Wei Li
Youzhi Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Oncology Inc
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Publication of AU2016247319A1 publication Critical patent/AU2016247319A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016247319A 2015-04-17 2016-04-18 Methods for treating cancer Abandoned AU2016247319A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562149349P 2015-04-17 2015-04-17
US62/149,349 2015-04-17
US201662280947P 2016-01-20 2016-01-20
US62/280,947 2016-01-20
PCT/US2016/028177 WO2016168856A1 (en) 2015-04-17 2016-04-18 Methods for treating cancer

Publications (1)

Publication Number Publication Date
AU2016247319A1 true AU2016247319A1 (en) 2017-11-02

Family

ID=55854799

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016247319A Abandoned AU2016247319A1 (en) 2015-04-17 2016-04-18 Methods for treating cancer

Country Status (16)

Country Link
US (1) US20180085341A1 (enExample)
EP (1) EP3283069A1 (enExample)
JP (1) JP2018511643A (enExample)
KR (1) KR20180006918A (enExample)
CN (1) CN107666906A (enExample)
AU (1) AU2016247319A1 (enExample)
BR (1) BR112017022281A2 (enExample)
CA (1) CA2983010A1 (enExample)
EA (1) EA201792287A1 (enExample)
HK (1) HK1250944A1 (enExample)
IL (1) IL255022A0 (enExample)
MX (1) MX2017013360A (enExample)
PH (1) PH12017501879A1 (enExample)
SG (2) SG11201708504XA (enExample)
TW (1) TW201713327A (enExample)
WO (1) WO2016168856A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027443T2 (en) 2007-09-10 2016-10-28 Boston Biomedical Inc A novel class of Stat3 pathway inhibitors and tumor stem cell inhibitors
JP6433085B2 (ja) 2013-04-09 2018-12-05 ボストン バイオメディカル， インコーポレイテッド がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
JP2019506392A (ja) * 2016-01-20 2019-03-07 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
EP3678663A4 (en) * 2017-09-05 2021-06-02 Epizyme, Inc. POLYTHERAPY FOR CANCER TREATMENT
EP3865130A4 (en) 2018-10-12 2022-07-20 1Globe Biomedical Co., Ltd. NEW COMBINATION SOLUTION FOR THE TREATMENT OF CHEMOTHERAPY-REFRACTORY CANCER
EP3705893A1 (en) * 2019-03-05 2020-09-09 Humanitas Mirasole S.p.A. Methods to assess the risk of being affected by prostate cancer
TW202102207A (zh) * 2019-03-27 2021-01-16 新加坡商新加坡保健服務集團有限公司 對於癌病具有治療意義的生物標記

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027443T2 (en) 2007-09-10 2016-10-28 Boston Biomedical Inc A novel class of Stat3 pathway inhibitors and tumor stem cell inhibitors
CN103002890A (zh) 2010-03-19 2013-03-27 波士顿生物医学公司 靶向癌症干细胞的新的化合物和组合物
CN103025159A (zh) 2010-03-19 2013-04-03 波士顿生物医学公司 靶向癌症干细胞的新方法
EP2681203A4 (en) 2011-03-04 2014-07-30 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co Ltd NOVEL 4,9-DIHYDROXY-NAPHTO [2,3-B] FURANS ESTERS FOR THERAPEUTIC TREATMENT OF DISEASES
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
JP6433085B2 (ja) * 2013-04-09 2018-12-05 ボストン バイオメディカル， インコーポレイテッド がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
JP2019506392A (ja) * 2016-01-20 2019-03-07 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法

Also Published As

Publication number Publication date
WO2016168856A1 (en) 2016-10-20
JP2018511643A (ja) 2018-04-26
IL255022A0 (en) 2017-12-31
CN107666906A (zh) 2018-02-06
HK1250944A1 (zh) 2019-01-18
EA201792287A1 (ru) 2018-03-30
BR112017022281A2 (pt) 2018-07-10
MX2017013360A (es) 2018-08-01
TW201713327A (zh) 2017-04-16
KR20180006918A (ko) 2018-01-19
SG10201900564WA (en) 2019-02-27
SG11201708504XA (en) 2017-11-29
EP3283069A1 (en) 2018-02-21
CA2983010A1 (en) 2016-10-20
PH12017501879A1 (en) 2018-03-05
US20180085341A1 (en) 2018-03-29

Similar Documents

Publication Publication Date Title
US20180085341A1 (en) Methods for treating cancer
US10646464B2 (en) Methods for treating cancer
US20190231735A1 (en) Methods for treating cancer
US20180250261A1 (en) Method for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
WO2018005444A2 (en) Methods for treating cancer
US20180098959A1 (en) Methods for treating cancer
CN113164438B (zh) 治疗化疗难治性癌症的新联合用药方案
HK40047114A (en) New combination solution for treating chemotherapy refractory cancer

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period